Henrik Schmidt
Aarhus University Hospital · 136 works · 14,135 citations · h-index 35
Top works
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
- Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
- An immune-active tumor microenvironment favors clinical response to ipilimumab
- A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma
- Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab
- Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
- Macrophage Markers in Serum and Tumor Have Prognostic Impact in American Joint Committee on Cancer Stage I/II Melanoma
- Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma
- Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression
- Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial
- Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody
- Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC stage I/II melanoma
- Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial
- Predictors of responses to immune checkpoint blockade in advanced melanoma
- Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma
- Interleukin-6 and melanoma
- Ipilimumab versus placebo after complete resection of stage III melanoma: Initial efficacy and safety results from the EORTC 18071 phase III trial.
- Elevated serum level of YKL‐40 is an independent prognostic factor for poor survival in patients with metastatic melanoma
- KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma